Effectiveness of an App Intervention to Reduce Postsurgical Symptom Distress in Patients With Vulvar Neoplasia
NCT ID: NCT04541784
Last Updated: 2021-09-22
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
NA
Total Enrollment
18 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-05-01
Study Completion Date
2021-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Despite great advances in surgical therapy in the last decades, symptom relief for women with vulvar neoplasia (vulvar cancer and pre-stage of vulvar cancer) is still not optimal. Guidelines of the National Comprehensive Cancer Network recommend using electronic communication media, e.g. applications ("apps") to relieve symptom distress and foster self-management. However, little is known on how effective these communication technologies are, especially in the field of a rare cancer disease like vulvar neoplasia. This mixed methods project aims to examine the effectiveness of a multidimensional mobile app intervention ("WOMAN-PRO III") focusing on possible improvements due to the new mobile app intervention, which consists of three counselling sessions with a gynaecologic-oncology nurse and the use of the mobile app whenever women want for a period of six months, the online version of the "WOMAN-PRO" diary for symptom assessment, the opportunity to send the data to the gynaecology-oncology nurse, disease and treatment related information and evidence-based recommendations, relevant contact data and a chat function for the anonymous exchange with peers (intervention group) compared to three counselling sessions with a gynaecologic-oncology nurse, where they receive written information (control group). Effectiveness will be examined with respect to symptom induced distress, uncertainty and cost effectiveness in women with vulvar neoplasia after surgical treatment across time.
The objective of the qualitative study is to assess women's perceived uncertainty and the acceptability, usability, strengths and weaknesses of the mobile app intervention ("WOMAN-PRO III") from patients' and gynaecology-oncology nurses' perspective.
The objective of the qualitative study is to assess women's perceived uncertainty and the acceptability, usability, strengths and weaknesses of the mobile app intervention ("WOMAN-PRO III") from patients' and gynaecology-oncology nurses' perspective.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of the "WOMAN-PRO II Program" on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence
NCT01986725
Vulvar Cancer
Vulvar Intraepithelial Neoplasia
COMPLETED
PHASE2
A New Patient Reported Outcome Instrument to Assess Symptom Experience in Women With Vulvar Neoplasms (WOMAN-PRO)
NCT01300663
Women With Vulvar Intraephitelial Neoplasia or Vulvar Cancer
UNKNOWN
Vaginal Laser Therapy in Breast Cancer Survivors
NCT03738605
Genitourinary Syndrome of Menopause
Vaginal Atrophy
Breast Cancer
+1 more
UNKNOWN
NA
Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function
NCT00588081
Vaginal Cancer
COMPLETED
NA
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
NCT02096783
Anxiety Disorder
Cervical Cancer
Endometrial Cancer
+8 more
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Vulvar neoplasia - incidence, symptoms and disease's management Although being a rare cancer disease, the incidence of vulvar neoplasia is increasing with a current incidence rate of 3.6 / 100.000 for women with vulvar cancer (Buttmann-Schweiger et al., 2015) and 7 / 100.000 for women with VIN (Anders, Riethdorf, \& Löning, 2001). Due to the disease itself and treatment side effects women suffer from a high number of postsurgical symptoms and related distress, such as pain, swelling, or uncertainty (Jefferies \& Clifford, 2012; Philp, Mellon, Barnett, D'Abrew, \& White, 2017; Senn et al., 2011). Results from literature suggest that women have unmet support needs as talking to healthcare professionals is perceived as difficult and information given by healthcare professionals is described as conflicting and inadequate (Philp et al., 2017). The high symptom prevalence and related distress reported uncertainty as well as the perceived lack of supportive care can lead to hospital readmissions and consequently to the generation of high healthcare costs.
To overcome this lack of supportive care, guidelines focusing on vulvar neoplasia recommend an integrative approach including skilled nursing as a key factor for patient management (Royal College of Obstetricians and Gynaecologists, 2014). Specialist nurses, i.e. Advanced Practice Nurses (APN) can, therefore, play an important role in caring for women with vulvar neoplasia, as shown in the study of Raphaelis et al. (2018) where women received written information and counselling sessions from APNs. However, gaps remain especially in women's disease management beyond the walls of the clinic. Therefore, supportive care interventions are requested to promote women's self-management, especially at home. One possibility might be the use of e-health.
E-health - the changing nature of self-help: E-health has come to be an important avenue for supporting self-management. One integral part of the subject area of e-health is m-health. Within the healthcare system the aim of m-health is to provide electronic solutions on mobile devices, which is also described in the WHO definition of m-health: "M-health covers medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other wireless devices" (World Health Organization, 2011). It is expected to contribute to patients' empowerment as they could take a more active role (European Commission, without date). Especially in chronic disease management, m-health interventions could play an important role in providing information and enabling communication without spatial and temporal restrictions.
Significance: This research will contribute significantly to the knowledge about effects of mobile app interventions in gynaecologic oncology, especially with regard to a reduction of symptom induced distress and improvement of uncertainty in a stigmatized disease like vulvar neoplasia.
Objectives: Primary Objective The study seeks primarily to examine the effectiveness of a multidimensional mobile app intervention, which consists of the use of the mobile app whenever women want for a period of six months and three counselling sessions with a gynaecology-oncology nurse ("WOMAN-PRO III") on symptom induced distress, uncertainty and cost-effectiveness in women with vulvar neoplasia after surgical treatment across time compared to three counselling sessions with a gynaecology-oncology nurse and written information. The secondary objective is to explore women's perceived uncertainty as well as the mobile app's acceptability, usability, strengths and weaknesses by assessing participants' and gynaecology-oncology nurses' experiences.
Methods: We use an explanatory-sequential design (Creswell \& Plano Clark, 2017) to examine the effectiveness of the mobile-app intervention ("WOMAN-PRO III"). Thus, quantitative findings can be explained by means of qualitative results (Creswell \& Plano Clark, 2017). Therefore, Phase 1 of this project will consist of a randomized controlled trial (RCT) with an intervention and control arm. Phase 2 is a subsequent qualitative study aiming to explore (1) women's meaning of uncertainty and (2) the mobile app intervention's ("WOMAN PRO III") acceptability, usability, strengths and weaknesses from patients' and gynaecology-oncology nurses' perspective.
Sample and setting: 100 Patients, with an estimated rate of 20% loss to follow-up and drop-out will be recruited continuously in four Swiss hospitals (Bern, Lucerne, Lugano, St.Gallen) to have in the end a total sample of 80 patients for analysis.
Recruitment: From May 1st, 2019 until January31st, 2021 patients will be consecutively invited by a gynaecologist or a nurse to participate in the study after initial diagnosis at the hospital.
Data collection: Will be conducted in the control group via paper-based questionnaires and in the intervention group via paper-based questionnaires and additionally via app. Patients will be asked to complete questionnaires at three points in time:
* Diagnosis / before surgical intervention (t0),
* day seven after surgery (t1),
* and month six after surgery (t2). Sample size: Statistical significance is defined as α = 0.05, power is defined as 80%. Assuming a 20% rate of loss to follow-up and drop-out, with a sampling ratio of 1 a total of 100 female patients with surgically treated VIN/VC will be necessary to start the randomized control trial to gain a total sample of 80 patients for analysis.
Planned analyses: Patients will be analyzed within their assigned groups (intention to treat) based on frequencies and descriptive statistics. Changes in symptom induced distress (frequency of symptoms, items and subscores) will be analyzed using mixed linear regression analysis, taking into account the longitudinal nature of the data (t0, t1, t2), and data clustering within centers. Fixed variables will be study group, point of time, and their interaction. The variables 'patient', nested under the respective 'center', will be entered as a random effect. To find out time-specific differences between the patient groups post-hoc tests will be performed. Uncertainty, our secondary outcome, will be analyzed similarly. Statistical analysis will be provided by a professional statistician, using IBM SPSS Version 24.
Qualitative study: After 6 months of collecting data for the RCT, a qualitative study will be started aiming to explore (1) women's perceived meaning and interaction concerning uncertainty and (2) the mobile app intervention's ("WOMAN PRO III") acceptability, usability, strengths and weaknesses from patients' and gynaecology-oncology nurses' perspective. Therefore, interviews will be conducted with women participating in the RCT and women who agreed to only participate in the qualitative study. Further, a focus group will be conducted with gynaecology-oncology nurses involved in the intervention tested.
Sample and setting: Women who have participated in Phase one of the mixed methods study will be considered as suitable to give insights about their meaning of uncertainty. As well, women who were not interested in participating in the RCT, but declared interest in participating in the qualitative study, are found to be eligible. Participants of the intervention and gynaecology-oncology nurses involved in the mobile app intervention (6 - 8 nurses) are considered eligible to deliver information about the mobile app intervention's ("WOMAN PRO III") acceptability, usability, strengths and weaknesses. It can be assumed, that with interviewing about 15 patients and involving 6 - 8 gynaecology-oncology nurses a first data saturation can be achieved.
Recruitment: Six months after surgery (t2) patients will be asked by a nurse not involved in the patients' treatment to indicate their willingness to participate in an individual interview. All gynaecology-oncology nurses involved in the mobile app intervention will be asked to participate in the focus group interview.
Data collection: The patient interviews and the focus group with the gynaecology-oncology nurses will be conducted by using interview guides consisting of open-ended questions. The interviews and the focus group will last about an hour. Patients' interviews will take place at the participant's home or in the clinical setting according to patient's preferences. The focus group interview will be held at a research institute. ¨ Data analysis: Data of the patient interviews and the focus group will be recorded, anonymized and transcribed verbatim (Dresing \& Pehl, 2011) and analyzed using open, axial and selective coding as proposed by Corbin \& Strauss (2015). The data analysis process will be conducted by researchers with extended experience in qualitative research and assisted by MAXQDA 2018 (VERBI GmbH, Berlin).
To overcome this lack of supportive care, guidelines focusing on vulvar neoplasia recommend an integrative approach including skilled nursing as a key factor for patient management (Royal College of Obstetricians and Gynaecologists, 2014). Specialist nurses, i.e. Advanced Practice Nurses (APN) can, therefore, play an important role in caring for women with vulvar neoplasia, as shown in the study of Raphaelis et al. (2018) where women received written information and counselling sessions from APNs. However, gaps remain especially in women's disease management beyond the walls of the clinic. Therefore, supportive care interventions are requested to promote women's self-management, especially at home. One possibility might be the use of e-health.
E-health - the changing nature of self-help: E-health has come to be an important avenue for supporting self-management. One integral part of the subject area of e-health is m-health. Within the healthcare system the aim of m-health is to provide electronic solutions on mobile devices, which is also described in the WHO definition of m-health: "M-health covers medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants (PDAs), and other wireless devices" (World Health Organization, 2011). It is expected to contribute to patients' empowerment as they could take a more active role (European Commission, without date). Especially in chronic disease management, m-health interventions could play an important role in providing information and enabling communication without spatial and temporal restrictions.
Significance: This research will contribute significantly to the knowledge about effects of mobile app interventions in gynaecologic oncology, especially with regard to a reduction of symptom induced distress and improvement of uncertainty in a stigmatized disease like vulvar neoplasia.
Objectives: Primary Objective The study seeks primarily to examine the effectiveness of a multidimensional mobile app intervention, which consists of the use of the mobile app whenever women want for a period of six months and three counselling sessions with a gynaecology-oncology nurse ("WOMAN-PRO III") on symptom induced distress, uncertainty and cost-effectiveness in women with vulvar neoplasia after surgical treatment across time compared to three counselling sessions with a gynaecology-oncology nurse and written information. The secondary objective is to explore women's perceived uncertainty as well as the mobile app's acceptability, usability, strengths and weaknesses by assessing participants' and gynaecology-oncology nurses' experiences.
Methods: We use an explanatory-sequential design (Creswell \& Plano Clark, 2017) to examine the effectiveness of the mobile-app intervention ("WOMAN-PRO III"). Thus, quantitative findings can be explained by means of qualitative results (Creswell \& Plano Clark, 2017). Therefore, Phase 1 of this project will consist of a randomized controlled trial (RCT) with an intervention and control arm. Phase 2 is a subsequent qualitative study aiming to explore (1) women's meaning of uncertainty and (2) the mobile app intervention's ("WOMAN PRO III") acceptability, usability, strengths and weaknesses from patients' and gynaecology-oncology nurses' perspective.
Sample and setting: 100 Patients, with an estimated rate of 20% loss to follow-up and drop-out will be recruited continuously in four Swiss hospitals (Bern, Lucerne, Lugano, St.Gallen) to have in the end a total sample of 80 patients for analysis.
Recruitment: From May 1st, 2019 until January31st, 2021 patients will be consecutively invited by a gynaecologist or a nurse to participate in the study after initial diagnosis at the hospital.
Data collection: Will be conducted in the control group via paper-based questionnaires and in the intervention group via paper-based questionnaires and additionally via app. Patients will be asked to complete questionnaires at three points in time:
* Diagnosis / before surgical intervention (t0),
* day seven after surgery (t1),
* and month six after surgery (t2). Sample size: Statistical significance is defined as α = 0.05, power is defined as 80%. Assuming a 20% rate of loss to follow-up and drop-out, with a sampling ratio of 1 a total of 100 female patients with surgically treated VIN/VC will be necessary to start the randomized control trial to gain a total sample of 80 patients for analysis.
Planned analyses: Patients will be analyzed within their assigned groups (intention to treat) based on frequencies and descriptive statistics. Changes in symptom induced distress (frequency of symptoms, items and subscores) will be analyzed using mixed linear regression analysis, taking into account the longitudinal nature of the data (t0, t1, t2), and data clustering within centers. Fixed variables will be study group, point of time, and their interaction. The variables 'patient', nested under the respective 'center', will be entered as a random effect. To find out time-specific differences between the patient groups post-hoc tests will be performed. Uncertainty, our secondary outcome, will be analyzed similarly. Statistical analysis will be provided by a professional statistician, using IBM SPSS Version 24.
Qualitative study: After 6 months of collecting data for the RCT, a qualitative study will be started aiming to explore (1) women's perceived meaning and interaction concerning uncertainty and (2) the mobile app intervention's ("WOMAN PRO III") acceptability, usability, strengths and weaknesses from patients' and gynaecology-oncology nurses' perspective. Therefore, interviews will be conducted with women participating in the RCT and women who agreed to only participate in the qualitative study. Further, a focus group will be conducted with gynaecology-oncology nurses involved in the intervention tested.
Sample and setting: Women who have participated in Phase one of the mixed methods study will be considered as suitable to give insights about their meaning of uncertainty. As well, women who were not interested in participating in the RCT, but declared interest in participating in the qualitative study, are found to be eligible. Participants of the intervention and gynaecology-oncology nurses involved in the mobile app intervention (6 - 8 nurses) are considered eligible to deliver information about the mobile app intervention's ("WOMAN PRO III") acceptability, usability, strengths and weaknesses. It can be assumed, that with interviewing about 15 patients and involving 6 - 8 gynaecology-oncology nurses a first data saturation can be achieved.
Recruitment: Six months after surgery (t2) patients will be asked by a nurse not involved in the patients' treatment to indicate their willingness to participate in an individual interview. All gynaecology-oncology nurses involved in the mobile app intervention will be asked to participate in the focus group interview.
Data collection: The patient interviews and the focus group with the gynaecology-oncology nurses will be conducted by using interview guides consisting of open-ended questions. The interviews and the focus group will last about an hour. Patients' interviews will take place at the participant's home or in the clinical setting according to patient's preferences. The focus group interview will be held at a research institute. ¨ Data analysis: Data of the patient interviews and the focus group will be recorded, anonymized and transcribed verbatim (Dresing \& Pehl, 2011) and analyzed using open, axial and selective coding as proposed by Corbin \& Strauss (2015). The data analysis process will be conducted by researchers with extended experience in qualitative research and assisted by MAXQDA 2018 (VERBI GmbH, Berlin).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Vulvar Neoplasm
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
SUPPORTIVE_CARE
Blinding Strategy
SINGLE
Outcome Assessors
The researchers and the statistician will be blinded to treatment assignment to prevent ascertainment bias.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
3 counselling sessions with gynaecology-oncology nurses
Patients randomized to the control group will receive standardized care, 3 counselling sessions with a gynaecology-oncology nurse and written information at three points in time during 6 months after diagnosis/surgery.
Group Type
ACTIVE_COMPARATOR
Three counselling sessions with gynaecology-oncology nurses
Intervention Type
OTHER
Standardized care, three counselling sessions with a gynaecology-oncology nurse.
Mobile app and 3 counselling sessions (WOMAN-PROIII)
Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app "WOMAN-PRO III". Counselling sessions will take place at 3 points in time during 6 months after diagnosis/surgery. Additionally, the gynaecology-oncology nurse will instruct the patient to use the mobile app. It includes a diary for symptom assessment and gives graphical feedback. Further, the app includes disease and treatment related information. If a symptom occurs the app will give an evidence-based recommendation (Kobleder et al., 2016). The patients can use the app whenever they want for a period of six months.
Group Type
EXPERIMENTAL
WOMAN-PRO III
Intervention Type
OTHER
Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app "WOMAN-PRO III".
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WOMAN-PRO III
Standardized care and three counselling sessions with a gynaecology-oncology nurse and the use of the mobile app "WOMAN-PRO III".
Intervention Type
OTHER
Three counselling sessions with gynaecology-oncology nurses
Standardized care, three counselling sessions with a gynaecology-oncology nurse.
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis VIN or vulvar cancer (primary diagnosis or recurrent neoplasia)
* Surgical treatment of VIN or vulvar cancer in one of the designated hospitals
* Sufficient knowledge of the German/Italian language (writing and speaking at level B1)
* Having a smartphone (e.g. iPhone, Samsung), tablet (e.g. iPad) or laptop (e.g. MacBook) for women participating in the quantitative study
* Informed Consent as documented by signature (Appendix Informed Consent Form)
* Surgical treatment of VIN or vulvar cancer in one of the designated hospitals
* Sufficient knowledge of the German/Italian language (writing and speaking at level B1)
* Having a smartphone (e.g. iPhone, Samsung), tablet (e.g. iPad) or laptop (e.g. MacBook) for women participating in the quantitative study
* Informed Consent as documented by signature (Appendix Informed Consent Form)
Exclusion Criteria
* Patients being judged by a physician or by a gynaecology-oncology nurse specialist as not being capable to participate in the trial and to complete the questionnaire due to:
* Cognitive, linguistic, emotional or physical reasons
* A present psychiatric treatment by reason of a main psychiatric diagnosis and the intake of psychopharmacological drugs
* Terminal illness
* Cognitive, linguistic, emotional or physical reasons
* A present psychiatric treatment by reason of a main psychiatric diagnosis and the intake of psychopharmacological drugs
* Terminal illness
Minimum Eligible Age
18 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cantonal Hospital of St. Gallen
OTHER
Sponsor Role
collaborator
Cantonal Hospital of Lucerne
UNKNOWN
Sponsor Role
collaborator
Regional Hospital of Lugano
UNKNOWN
Sponsor Role
collaborator
Insel Gruppe AG, University Hospital Bern
OTHER
Sponsor Role
collaborator
St.Gallen University of Applied Sciences
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea Kobleder
Principal Investigator
Responsibility Role
PRINCIPAL_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cantonal Hospital of St. Gallen
Sankt Gallen, Canton of St. Gallen, Switzerland
Site Status
Regional Hospital of Lugano
Lugano, Canton Ticino, Switzerland
Site Status
University Hospital of Bern
Bern, , Switzerland
Site Status
Cantonal Hospital of Lucerne
Lucerne, , Switzerland
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Switzerland
References
Explore related publications, articles, or registry entries linked to this study.
Broglia E, Millings A, Barkham M. Comparing counselling alone versus counselling supplemented with guided use of a well-being app for university students experiencing anxiety or depression (CASELOAD): protocol for a feasibility trial. Pilot Feasibility Stud. 2017 Jan 23;3:3. doi: 10.1186/s40814-016-0119-2. eCollection 2017.
Reference Type
BACKGROUND
Buttmann-Schweiger N, Klug SJ, Luyten A, Holleczek B, Heitz F, du Bois A, Kraywinkel K. Incidence patterns and temporal trends of invasive nonmelanotic vulvar tumors in Germany 1999-2011. A population-based cancer registry analysis. PLoS One. 2015 May 28;10(5):e0128073. doi: 10.1371/journal.pone.0128073. eCollection 2015.
Reference Type
BACKGROUND
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008 Sep 29;337:a1655. doi: 10.1136/bmj.a1655.
Reference Type
BACKGROUND
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research; U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006 Oct 11;4:79. doi: 10.1186/1477-7525-4-79.
Reference Type
BACKGROUND
Gray HJ. Advances in vulvar and vaginal cancer treatment. Gynecol Oncol. 2010 Jul;118(1):3-5. doi: 10.1016/j.ygyno.2010.04.011. Epub 2010 May 15. No abstract available.
Reference Type
BACKGROUND
Graziottin A, Serafini A. HPV infection in women: psychosexual impact of genital warts and intraepithelial lesions. J Sex Med. 2009 Mar;6(3):633-45. doi: 10.1111/j.1743-6109.2008.01151.x. Epub 2009 Jan 13.
Reference Type
BACKGROUND
Jefferies H, Clifford C. Invisibility: the lived experience of women with cancer of the vulva. Cancer Nurs. 2012 Sep-Oct;35(5):382-9. doi: 10.1097/NCC.0b013e31823335a1.
Reference Type
BACKGROUND
Kaushik S, Pepas L, Nordin A, Bryant A, Dickinson HO. Surgical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Database Syst Rev. 2014 Mar 4;2014(3):CD007928. doi: 10.1002/14651858.CD007928.pub3.
Reference Type
BACKGROUND
Kobleder A, Raphaelis S, Glaus A, Fliedner M, Mueller MD, Gafner D, Gehrig L, Senn B. Recommendations for symptom management in women with vulvar neoplasms after surgical treatment: An evidence-based guideline. Eur J Oncol Nurs. 2016 Dec;25:68-76. doi: 10.1016/j.ejon.2016.10.003. Epub 2016 Oct 22.
Reference Type
BACKGROUND
Leermakers ME, Pleunis N, Boll D, Hermans RH, Ezendam NP, Pijnenborg JM. High Incidence of Erysipelas After Surgical Treatment for Vulvar Carcinoma: An Observational Study. Int J Gynecol Cancer. 2016 Mar;26(3):582-7. doi: 10.1097/IGC.0000000000000625.
Reference Type
BACKGROUND
McFadden KM, Sharp L, Cruickshank ME. The prospective management of women with newly diagnosed vulval intraepithelial neoplasia: clinical outcome and quality of life. J Obstet Gynaecol. 2009 Nov;29(8):749-53. doi: 10.3109/01443610903191285.
Reference Type
BACKGROUND
Mishel MH. The measurement of uncertainty in illness. Nurs Res. 1981 Sep-Oct;30(5):258-63.
Reference Type
BACKGROUND
Philp S, Mellon A, Barnett C, D'Abrew N, White K. The road less travelled: Australian women's experiences with vulval cancer. Eur J Cancer Care (Engl). 2017 Jan;26(1). doi: 10.1111/ecc.12465. Epub 2016 Feb 18.
Reference Type
BACKGROUND
Raphaelis S, Mayer H, Ott S, Mueller MD, Steiner E, Joura E, Senn B. The impact of written information and counseling (WOMAN-PRO II Program) on symptom outcomes in women with vulvar neoplasia: A multicenter randomized controlled phase II study. Gynecol Oncol. 2017 Jul;146(1):114-122. doi: 10.1016/j.ygyno.2017.04.024. Epub 2017 May 5.
Reference Type
BACKGROUND
Raphaelis S, Mayer H, Ott S, Hornung R, Senn B. Effects of Written Information and Counseling on Illness-Related Uncertainty in Women With Vulvar Neoplasia. Oncol Nurs Forum. 2018 Nov 1;45(6):748-760. doi: 10.1188/18.ONF.748-760.
Reference Type
BACKGROUND
Senn B, Gafner D, Happ MB, Eicher M, Mueller MD, Engberg S, Spirig R. The unspoken disease: symptom experience in women with vulval neoplasia and surgical treatment: a qualitative study. Eur J Cancer Care (Engl). 2011 Nov;20(6):747-58. doi: 10.1111/j.1365-2354.2011.01267.x. Epub 2011 Jul 19.
Reference Type
BACKGROUND
Senn B, Eicher M, Mueller MD, Hornung R, Fink D, Baessler K, Hampl M, Denhaerynck K, Spirig R, Engberg S. A patient-reported outcome measure to identify occurrence and distress of post-surgery symptoms of WOMen with vulvAr Neoplasia (WOMAN-PRO) - a cross sectional study. Gynecol Oncol. 2013 Apr;129(1):234-40. doi: 10.1016/j.ygyno.2012.12.038. Epub 2013 Jan 3.
Reference Type
BACKGROUND
Senn B, Mueller MD, Cignacco EL, Eicher M. Period prevalence and risk factors for postoperative short-term wound complications in vulvar cancer: a cross-sectional study. Int J Gynecol Cancer. 2010 May;20(4):646-54. doi: 10.1111/IGC.0b013e3181d92723.
Reference Type
BACKGROUND
Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, Van Dorst EB, Van der Velden J, Hermans RH, van der Putten H, Drouin P, Schneider A, Sluiter WJ. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008 Feb 20;26(6):884-9. doi: 10.1200/JCO.2007.14.0566.
Reference Type
BACKGROUND
Senn, B., Gafner, D., Raphaelis, S., Meyer, G., Mayer, H., White, K.,. . . Mueller, M. D. (2013). Testing the counsellig program
Reference Type
BACKGROUND
Lincoln, Y. S., & Guba, E. G. (1985). Naturalistic inquiry. Beverly Hills, Calif.: Sage Publications.
Reference Type
BACKGROUND
Hampl, M., & Janni, W. (2012). Vulvakarzinom. Der Gynäkologe, 45(11), 865-872. https://doi.org/10.1007/s00129-012-2995-8
Reference Type
BACKGROUND
Grove, S. K., Burns, N. P. D., & Gray, J. 1. (2012). The practice of nursing research: Appraisal, synthesis, and generation of evidence (7. ed.). Philadelphia Pa., London: Saunders.
Reference Type
BACKGROUND
Flick, U. (2014). An introduction to qualitative research (Ed. 5). Los Angeles, Calif.: Sage.
Reference Type
BACKGROUND
Dresing, T., & Pehl, T. (2011). Praxisbuch Transkription: Regelsysteme, Software und praktische Anleitungen für qualitative ForscherInnen (2. Auflage, Sept. 2011). Marburg: Eigenverlag.
Reference Type
BACKGROUND
Denzin, N. K., & Lincoln, Y. S. (2011). The Sage handbook of qualitative research (4th ed.). Thousand Oaks: Sage.
Reference Type
BACKGROUND
Creswell, J. W., & Plano Clark, V. L. (2017). Designing and conducting mixed methods research (3rd ed.). Los Angeles: Sage Publications.
Reference Type
BACKGROUND
Anders, S., Riethdorf, L., & Löning, T. (2001). Neoplasia and pre-neoplasia of the lower genital tract. Der Gynäkologe, 34(7), 590-598. https://doi.org/10.1007/s001290101061
Reference Type
BACKGROUND
Related Links
Access external resources that provide additional context or updates about the study.
https://www.rcog.org.uk/globalassets/documents/guidelines/vulvalcancerguideline.pdf
Royal College of Obstetricians and Gynaecologists. (2014). Guideline for Diagnosis and Management of Vulval Carcinoma.
https://www.admin.ch/opc/de/classified-compilation/19920153/201401010000/235.1.pdf
Swiss Confederation. (2014). Federal Law on Data Protection.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WOMAN-PRO III
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Pelvic Physical Therapy for Sexual Dysfunction in Gynecologic Oncology Survivors
NCT05242770
COMPLETED
NA
Evaluation of Vaginal Dose in Cervical Cancer Patients Treated With Radiotherapy
NCT03257475
UNKNOWN
The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Cervical Cancer Research
NCT02018003
UNKNOWN
Laser Therapy for Vulvovaginal Symptoms in Breast Cancer Patients
NCT03628092
UNKNOWN
NA
Impact of Cancer Treatment on the Pelvic Floor Function in Survivors of Cervical Cancer
NCT03188744
UNKNOWN
Sexual Quality of Life of Patients With Gynecologic Cancer Treated With Brachytherapy.
NCT04184154
COMPLETED
Evaluation of The Vaginal Renewal™ Program in Gynecologic Cancer Patients Experiencing Sexual Dysfunction
NCT01444911
TERMINATED
PHASE2
Feasibility Study of a Prospective and Pragmatic Cohort
NCT02864797
UNKNOWN
NA
To Explore the Benefits of the MonaLisa Touch® System in Gynaecological Cancer Patients Treated by (Chemo)-RT
NCT05891470
RECRUITING
NA
Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation Therapy
NCT04713618
ACTIVE_NOT_RECRUITING
Post-Operative Gynecological Oncology App Study
NCT02932098
COMPLETED
NA
Outcomes From Home in Patients Recovering From Major Gynecologic Cancer Surgery: Measuring Symptoms and Health-related Quality of Life
NCT00870233
COMPLETED
Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
NCT03956498
COMPLETED
NA
Electrochemotherapy for the Inoperable Vulva Carcinoma
NCT03142061
COMPLETED
NA
Questionnaire Study for Gynecological Cancer Survivors
NCT00391664
UNKNOWN
A Multimodal Intervention Program to Improve Sexual Health and Self-perceived Quality of Life in Patients Treated for Cervical Cancer (PROVIDENCE)
NCT06031493
UNKNOWN
PHASE4
Clinical Performance and Safety of the VITA AV Clinical System
NCT06207227
COMPLETED
NA
Radiation Therapy or Surgery in Treating Patients With Previously Untreated Vulva Cancer With Positive Groin Lymph Nodes
NCT00898352
COMPLETED
PHASE3
A Novel Tapered Applicator for Vaginal Vault Brachytherapy
NCT04318340
COMPLETED
NA
Early Detection of Cancers in Low Resource Countries
NCT01178736
UNKNOWN
Person-centred Support for Women After Treatment for Gynaecological Cancer
NCT01784406
COMPLETED
NA
Perineal Massage in Women With Gynecological Cancer
NCT06432998
RECRUITING
NA
Promotion of Vaginal Health With CH2 Vaginal Gel After Pelvic Radiotherapy
NCT06997887
RECRUITING
NA
Management With Fear of Cancer in Women Undergoing Colposcopy: Randomized Controlled Study
NCT06263062
RECRUITING
NA